ALPS Medical Breakthroughs ETF (SBIO - Free Report) – Up 29.9%

This fund provides exposure to companies with one or more drugs in phase II or phase III FDA clinical trials by tracking S-Network Medical Breakthroughs Index. It holds 91 securities in its basket. The product charges 50 basis points in fees per year from its investors and trades in a moderate average daily volume of about 47,000 shares. It has AUM of $242.5 million in its asset base and carries a Zacks ETF Rank #3 with a High risk outlook.